TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04747951

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemoradiotherapy
Description: 50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: 50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: Total mesorectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
Study: NCT02352987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem plus propylene glycol plus salicylic acid
Description: Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic acid
Description: salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Study: NCT00505661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg PO Once Daily
Study: NCT01811836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
Study: NCT00860041

Intervention type: BEHAVIORAL
Intervention: pain questionnaires

Intervention type: BEHAVIORAL
Intervention: pain questionnaires

Intervention type: BEHAVIORAL
Intervention: pain questionnaires

Intervention type: BEHAVIORAL
Intervention: pain questionnaires
Study: NCT00365209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Given orally
Study: NCT01801241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomic TSA using IRI Instrumentation
Description: Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Total Shoulder Arthroplasty
Description: Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Total Shoulder Arthroplasty
Description: Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
Study: NCT02537834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofogliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue
Study: NCT05051800

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Program to Support Coping and Communication in Families
Description: Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Program to Support Coping and Communication in Families
Description: Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
Study: NCT02098616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325 + RBV
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325 + RBV
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325 + RBV
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
Study: NCT00303212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
Study: NCT04531982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
Study: NCT04588896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
Study: NCT04531982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two blinded tablets once daily by mouth
Study: NCT03240224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study: NCT04588896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Description: Lifestyle modification programme

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification programme
Description: Lifestyle modification programme
Study: NCT02501759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gadodiamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal Biopsy
Description: Undergo transrectal MRI-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Prostate Biopsy
Description: Undergo TRUS-guided biopsy
Study: NCT02788006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg
Study: NCT02904109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Once daily oral administration of 600 mg triflusal Disgren® for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Once daily oral administration of 600 mg triflusal Disgren® for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral administration of placebo mannitol for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral administration of placebo mannitol for 8 days.
Study: NCT00982982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC and Iomazenil
Description: * Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (control)
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
Study: NCT01951092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging
Study: NCT00253279

Intervention type: PROCEDURE
Intervention: PET Scans
Description: Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.

Intervention type: PROCEDURE
Intervention: PET Scans
Description: Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
Study: NCT01410461

Intervention type: DEVICE
Intervention: quantitive sensory testing
Description: Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer

Intervention type: DEVICE
Intervention: Ultrasound testing
Description: Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
Study: NCT02591680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strengthening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensorimotor
Study: NCT01416896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis using the standard venous needle
Description: Hemodialysis using the standard venous dialysis needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis using a new venous needle, the BME needle
Description: Hemodialysis using a new venous dialysis needle or the BME needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis using a new venous needle, the BME needle
Description: One hemodialysis using a new venous needle, the BME needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis using the standard venous needle
Description: One hemodialysis using the standard venous needle
Study: NCT04415385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg, orally once a day. Take about half an hour after a meal with warm water.
Study: NCT01227408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
Description: doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
Study: NCT04356339

Intervention type: DRUG
Intervention: Interferon-beta-1b (BETASERON, BAY 86-5046)
Description: Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
Study: NCT04325464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-003A
Description: PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
Study: NCT01397565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy performed using minilaparoscopic instruments
Study: NCT02973360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT02337478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given via injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02936622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® Paclitaxel-Eluting Peripheral Stent
Description: Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
Description: Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
Description: Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Study: NCT03910348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise
Description: The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
Study: NCT03240224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT03258008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
Study: NCT00709007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART)
Description: Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAT
Description: Participants take their HIV medications by themselves.
Study: NCT01023841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Sterile Solution
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Study: NCT01718145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegIFNα-2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study: NCT00772824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 2g/kg body weight twice daily in divided doses for 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IV Glutamine
Description: 50 ml of 20% glutamine IV before chemotherapy
Study: NCT02672358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral Dabrafenib 150 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral Trametinib 2 mg QD
Study: NCT04106362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT01004601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
Study: NCT04015518

Intervention type: DRUG
Group type: OTHER
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
Study: NCT01651338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.